Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $28.60, for a total value of $65,551.20. Following the sale, the chief executive officer owned 139,792 shares in the company, valued at $3,998,051.20. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Stock Up 1.2%

NASDAQ PHVS traded up $0.35 during trading hours on Monday, reaching $28.93. 88,705 shares of the company were exchanged, compared to its average volume of 170,640. The stock has a market capitalization of $1.89 billion, a P/E ratio of -8.57 and a beta of -2.58. Pharvaris N.V. has a 1 year low of $13.81 and a 1 year high of $29.89. The business’s 50 day simple moving average is $27.25 and its 200-day simple moving average is $25.68.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). As a group, sell-side analysts anticipate that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PHVS shares. Wolfe Research began coverage on shares of Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Wedbush lifted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $42.73.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its position in Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares during the period. venBio Partners LLC grew its holdings in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP increased its position in shares of Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.